Effectiveness of an Secondary Prevention Program in Chronic Kidney Disease

Carlos Enrique Yepes Delgado, Yanett Marcela Montoya Jaramillo, Beatriz Elena Orrego Orozco, Paulina Bernal Ramírez, Luz Denise González, José Miguel Abad Echeverri, María Patricia Arbeláez Montoya

University of Antioquia, Hospital Pablo Tobón Uribe, EPS SURA, Medellín, Colombia.

DOI: 10.4236/ojneph.2013.33026                

Abstract

Background: There are many programs which focus on late-stage chronic kidney disease (CKD), and it is considered that further evidence needs to be generated regarding the effectiveness of the programs used before renal replacement therapy. Study Design: A cohort study. Settings & Participants: Patients over 15 years of age who had been diagnosed with CKD according to the KDOQI (Kidney Disease Outcomes Quality Initiative) guidelines and who had undergone conventional treatment (CT) or a renal protection program (RPP). These were patients of two Colombian health insurance companies. Predictors: Age, sex, marital status, comorbidities, CKD stage, and clinical indicators. Outcomes: First CKD progression, and need for renal replacement therapy (RRT). Measures: Clinical marker. Results: The RPP is structurally and functionally different from the CT. It offers the interdisciplinary management of patients, a greater number of medical appointments, and patients start to receive treatment at younger ages and at earlier stages of their condition. The clinical markers of the patients following the RPP are within adequate ranges, and their renal function is less impaired, despite the differences in basal conditions. Upon finishing the study, we found that patients who received CT had a higher risk of receiving nephrotoxic drugs and not receiving nephroprotective drugs. The explanatory variables for the first progression were age, stage, history of dyslipidemia, and hemoglobin, potassium, and albumin levels. These variables, together with glycemia levels were also valid for RRT, except for history of dyslipidemia, as it was not significant. Upon adjusting for the explanatory variables, it was found that belonging to the RPP and attending more appointments had a protective effect in the process of controlling renal damage. Limitations: A possible selection bias. Conclusions: Belonging to a structured renal protection program is an effective way to keeping the clinical markers associated with renal impairment within normal ranges.

Keywords

Chronic Kidney Disease; Renal Protection Program; Effectiveness; Clinical Markers; Progression of Renal Damage; Renal Replacement Program

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. C. Atkins, “The Epidemiology of Chronic Kidney Disease,” Kidney International Supplement, Vol. 94, 2005, pp. S14-18. doi:10.1111/j.1523-1755.2005.09403.x
[2]	R. C. Atkins, “The Changing Patterns of Chronic Kidney Disease: The Need to Develop Strategies for Prevention Relevant to Different Regions and Countries,” Kidney International Supplement, Vol. 98, 2005, pp. S83-85. doi:10.1111/j.1523-1755.2005.09815.x
[3]	R. S. Barsoum, “Chronic Kidney Disease in the Developing World,” The New England Journal of Medicine, Vol. 354, No. 10, 2006, pp. 997-999. doi:10.1056/NEJMp058318
[4]	S. L. White, A. Cass, R. C. Atkins and S. J. Chadban, “Chronic Kidney Disease in the General Population,” Advances in Chronic Kidney Disease, Vol. 12, No. 1, 2005, pp. 5-13. doi:10.1053/j.ackd.2004.10.009
[5]	N. Lameire, K. Jager, W. Van Biesen, D. de Bacquer and R. Vanholder, “Chronic Kidney Disease: A European Perspective,” Kidney International Supplement, Vol. 99, 2005, pp. S30-38. doi:10.1111/j.1523-1755.2005.09907.x
[6]	Cuenta de Alto Costo, “Contenidos Mínimos Indispensables Para la Gestión Del Riesgo Renal en un Programa de Atención a Pacientes Adultos con Enfermedad Renal Crónica, Sin Terapia de Reemplazo Renal en Colombia, Definiciones Técnicas Basadas en Evidencias,” 2011. http://www.cuentadealtocosto.org/patologias/ERC/docs/consenso/programas_ERC.pdf
[7]	Ministerio de la Protección Social, República de Colombia, “Guía Para el Manejo de la Enfermedad Renal Crónica y Modelo de Prevención y Control de la Enfermedad Renal Crónica. Componente de un Modelo de Salud Renal,” 2011. http://pos.gov.co/Documents/Archivos/ERC.pdf
[8]	F. Martínez and M. Valencia “Modelo en Prevención y Control de la Enfermedad Renal Crónica. Componente de un Modelo de Salud Renal,” Bogotá, 2005.
[9]	Ministerio de Protección Social, República de Colombia, “Cuenta de Alto Costo,” 2011. http://www.cuentadealtocosto.org/CAC.html
[10]	B. M. Curtis, P. Ravani, F. Malberti, F. Kennett, P. A. Taylor, O. Djurdjev and A. Levin, “The Shortand LongTerm Impact of Multi-Disciplinary Clinics in Addition to Standard Nephrology Care on Patient Outcomes,” Nephrology Dialysis Transplantation, Vol. 20, No. 1, 2005, pp. 147-154. doi:10.1093/ndt/gfh585
[11]	C. Black, P. Sharma, G. Scotland, K. McCullough, D. McGurn, L. Robertson, N. Fluck, A. MacLeod, P. McNamee, G. Prescott and C. Smith, “Early Referral Strategies for Management of People with Markers of Renal Disease: A Systematic Review of the Evidence of Clinical Effectiveness, Cost-Effectiveness and Economic Analysis,” Health Technology Assessment, Vol. 14, No. 21, 2010, pp. 1-184.
[12]	R. Pellicano, P. G. Kerr and R. C. Atkins, “What Have We Learned from Clinical Trials on Prevention?” Kidney International Supplement, Vol. 94, 2005, pp. 101-106. doi:10.1111/j.1523-1755.2005.09424.x
[13]	L. D. B. Gray, “Outcomes Research in Nutrition and Chronic Kidney Disease: Perspectives, Issues in Practice, and Processes for Improvement,” Advances in Chronic Kidney Disease, Vol. 12, No. 1, 2005, pp. 96-106. doi:10.1053/j.ackd.2004.10.012
[14]	M. M. Slowik, “Early Education of Patients with Chronic Renal Insufficiency: The Healthy Start program. Case Study of the Anemic Patient,” Nephrology Nursing Journal, Vol. 28, No. 6, 2001, pp. 643-646.
[15]	K. Tungsanga, C. Ratanakul, W. Pooltavee, N. Mahatanan, A. I. Na Ayuthaya and S. Rodpai, “Experience with Prevention Programs in Thailand,” Kidney International Supplement, Vol. 94, 2005, pp. 68-69. doi:10.1111/j.1523-1755.2005.09417.x
[16]	R. T. Gansevoort, Van der Heij, C. A. Stegeman, F. T. De Charro, M. G. Nieuwenhuizen and D. De Zeeuw, “Trends in the Incidence of Treated End-Stage Renal Failure in the Netherlands: Hope for the Future?” Kidney International Supplement, Vol. 92, 2004, pp. 7-10. doi:10.1111/j.1523-1755.2004.09202.x
[17]	National Kidney Foundation, “K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification,” Recommendations for clinical Performance Measures, 2007. http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p8_cpm.htm
[18]	M. Katz, “Multivariable Analysis. A Practical Guide for Clinicians,” 2nd Edition, Cambridge, 2006.
[19]	A. Ruiz and L. Morillo, “Epidemiología Clínica. Investigación Clínica Aplicada,” Editorial Panamericana, Bogotá, 2004.
[20]	H. Tazeen, “The Growing Burden of Chronic Kidney Disease in Pakistan,” The New England Journal of Medicine, Vol. 9, No. 10, 2006, pp. 995-997.
[21]	B. J. Barrett, “Applying Multiple Interventions in Chronic Kidney Disease,” Seminars in Dialysis, Vol. 16, No. 2, 2003, pp. 157-164. doi:10.1046/j.1525-139X.2003.16032.x
[22]	D. C. Mendelssohn, “Coping with the CKD Epidemic: The Promise of Multidisciplinary Team-Based Care,” Nephrology Dialysis Transplantation, Vol. 20, No. 1, 2005, pp. 10-12. doi:10.1093/ndt/gfh636
[23]	R. Pellicano, R. C. Atkins and P. G. Kerr, “What Have We Learned from Clinical Trials on Prevention?” Kidney International Supplement, Vol. 94, 2005, pp. 101-106. doi:10.1111/j.1523-1755.2005.09424.x
[24]	B. J. Pereira, “Overcoming Barriers to the Early Detection and Treatment of Chronic Kidney Disease and Improving Outcomes for End-Stage Renal Disease,” American Journal of Managed Care, Vol. 8, No. 4, 2002, pp. S122-S135.
[25]	“Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment Discussion and Consensus of Presentations of Economic Analyses, Managed Care Organization Case Studies, and Opportunities for Intervention in a Managed Care Setting,” American Journal of Managed Care, Vol. 8, No. 4, 2002, pp. S114-S120.
[26]	A. Levin, “The Need for Optimal and Coordinated Management of CKD,” Kidney International, Vol. 68, No. 99, 2005, pp. S7-S10.
[27]	W. F. Owen, “Patterns of Care for Patients with Chronic Kidney Disease in the United States: Dying for Improvement,” Journal of the American Society of Nephrology, Vol. 14, No. 2, 2003, pp. 76-80. doi:10.1097/01.ASN.0000070145.00225.EC
[28]	Grupo de Economía de la Salud, “Evaluación Económica en Salud: Tópicos Teóricos y Aplicaciones en Colombia,” Observatorio de la Seguridad Social, 2006.
[29]	B. Manns, B. Hemmelgan, M. Tonelli, Au Flora, T. C. Chiasson, J. Dong and S. Klarenbach, “Population Based Screening for Chronic Kidney Disease: Cost Effectiveness Study,” BMJ, Vol. 341, 2010, p. 5869.